Champions Oncology, Inc. CSBR
Set alert
4.81 USD 0.00 0.00%
At close · Oct 30
4.81 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
4.76 Day range 4.95
4.69 52-week range 7.80
- YTD
- -30.39%
- 1 year
- -29.37%
- Open
- 4.86
- Prev close
- 4.81
- Mkt cap
- 66.95M
- Vol
- 8.44K
- Avg vol
- 10.78K
- EPS
- -0.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.76
- High
- 4.95
- Forward P/E
- 42.68
- Beta
- 0.49
- Short ratio
- 20.86
- Inst. own
- 49.09%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.71
- 200-d avg
- 4.79
- 1y target
- 8.00
6M chart
Signals (33)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 26, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 12, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 24, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 9, 2026 | 3 months ago |
| SMA: Bullish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 2, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| RSI: Overbought | Jun 16, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| MACD: Sell Signal | May 21, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 5 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
Key statistics
- Market cap
- 111.10M
- Enterprise value
- 89.18M
- Trailing P/E
- 0.00
- Forward P/E
- 42.68
- PEG ratio
- 0.00
- Price / sales
- 2.15
- Price / book
- 0.00
- EPS (TTM)
- -0.05
- Beta
- 0.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -6.58%
- Revenue (TTM)
- 51.66M
- Revenue growth
- 11.90%
- Free cash flow
- -837.50K
- Total cash
- 2.89M
- Total debt
- 7.11M
- Return on equity
- -432.46%
- Shares outstanding
- 13.70M
- Short % of float
- 3.96%
- 50-day average
- 4.71
- 200-day average
- 4.79
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 8.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.01.
Financials — quick view
CSBR Revenue — quarterly 15.23M
CSBR Net income — quarterly -426.00K
CSBR EPS — quarterly -0.03
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 11, 2024 | Oct 1, 2024 | 0.00 | 0.05 | — | — |
| Sep 11, 2024 | Jul 1, 2024 | 0.00 | 0.09 | — | — |
| Jul 18, 2024 | Apr 1, 2024 | 0.00 | -0.01 | — | — |
| Mar 12, 2024 | Jan 1, 2024 | 0.00 | -0.19 | — | — |
| Dec 12, 2023 | Oct 1, 2023 | -0.17 | -0.15 | +0.02 | +11.76% |
| Sep 13, 2023 | Jul 1, 2023 | 0.00 | -0.19 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | Craig-Hallum | main | Buy | Buy |
| Sep 12, 2024 | Craig-Hallum | up | Hold | Buy |
| Mar 13, 2024 | Craig-Hallum | down | Buy | Hold |
| Sep 22, 2023 | Roth MKM | main | Buy | Buy |
| Mar 15, 2021 | Roth Capital | main | — | Buy |
| Nov 18, 2019 | Benchmark | init | — | Speculative Buy |
About Champions Oncology, Inc.
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- championsoncology.com
News
- Champions Oncology Q4 2026 Earnings Call Transcript
- Champions Oncology Q3 2026 Earnings Call Transcript
- Full Transcript: Champions Oncology Q1 2027 Earnings Call
- Full Transcript: Champions Oncology Q4 2026 Earnings Call
- CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
- Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript
- Champions Oncology Q1 Earnings Call Highlights
- Champions Oncology Q1 Adj. EPS $0.05 Up From $0.01 YoY, Sales $15.232M Up From $13.995M YoY
- Champions Oncology Reports Revenue of $15.2 Million
- Champions Oncology Expands Radiopharmaceutical Platform With In-House SPECT/CT Imaging For Integrated Tumor Biology And Efficacy Insights
Your note
Sign in to keep a note on CSBR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ACKERMAN JOEL | Director | Conversion of Exercise of derivative security | Oct 30, 2024 | 962,134 |
| MENDELSON DANIEL NEWMAN | Director | Purchase | Jan 11, 2024 | 198,625 |
| MORRIS RONNIE | Chief Executive Officer | Purchase | Mar 16, 2023 | 858,878 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Battery Management Corp. | 17.52% | 2,421,673 | 19.64M | Sep 29, 2024 |
| NEA Management Company, LLC | 12.40% | 1,713,720 | 13.90M | Sep 29, 2024 |
| Tocqueville Asset Management L.p. | 5.10% | 705,214 | 5.72M | Sep 29, 2024 |
| Vanguard Group Inc | 2.22% | 307,002 | 2.49M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.87% | 119,991 | 973.13K | Sep 29, 2024 |
| Blackrock Inc. | 0.84% | 116,191 | 942.31K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.71% | 235,738 | 1.91M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.50% | 69,171 | 560.98K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 31,531 | 255.72K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.11% | 15,857 | 128.60K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.08% | 10,958 | 88.87K | Oct 30, 2024 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.05% | 6,854 | 55.59K | Jul 30, 2024 |